Myokardia Inc (OQ:MYOK)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 333 Allerton Ave
Tel: 1-650-3514690
IR: See website
Key People
Tassos Anastasios Gianakakos
President, Chief Executive Officer, Director
Taylor C. Harris
Chief Financial Officer
William C. Fairey
Executive Vice President and Chief Commercial Officer
June Lee
Executive Vice President, Chief Development Officer
Joseph Lee Lambing
Senior Vice President - Nonclinical and Pharmaceutical Development
Robert Scott McDowell
Senior Vice President - Drug Discovery
Cynthia J. Ladd
General Counsel
Jake Bauer
Chief Business Officer
Marc Semigran
Chief Medical Officer
Business Overview
MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics. The Company has used its precision medicine platform to generate an initial pipeline of over four therapeutic programs for the chronic treatment of two forms of heritable cardiomyopathy-hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). Additionally, the Company has three preclinical programs, HCM-2, DCM-2 and LUS-1. Its lead product candidate, MYK-461, is an orally-administered small molecule designed to reduce excessive cardiac muscle contractility leading to HCM.
Financial Overview
For the nine months ended 30 September 2019, Myokardia Inc revenues decreased from $21.2M to $0K. Net loss increased from $52M to $217.4M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - Balancing increase from $44.1M to $90.9M (expense), General and administrative - Balancing increase of 65% to $31.7M (expense).
Employees: 220 as of Sep 30, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $2,771M as of Sep 30, 2019
Annual revenue (TTM): $12.40M as of Sep 30, 2019
EBITDA (TTM): -$242.43M as of Sep 30, 2019
Net annual income (TTM): -$233.12M as of Sep 30, 2019
Free cash flow (TTM): -$209.03M as of Sep 30, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 46,225,917 as of Oct 30, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization